Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(11):1443–1446. doi: 10.1054/bjoc.2001.1725

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

C A Maxwell-Armstrong 1, L G Durrant 2, T J D Buckley 1, J H Scholefield 1, R A Robins 3, K Fielding 4, J R T Monson 5, P Guillou 6, H Calvert 7, J Carmichael 2, J D Hardcastle 1
PMCID: PMC2363670  PMID: 11384090

Abstract

The cancer vaccine 105AD7 is an anti-idiotypic monoclonal antibody that mimics the tumour-associated antigen 791T/gp72 (CD55, Decay Accelerating Factor) on colorectal cancer cells. Phase I studies in patients with advanced disease confirmed that 105AD7 is non-toxic, and that T cell responses could be generated. A prospective, randomized, double-blind, placebo-controlled survival study in patients with advanced colorectal cancer was performed. 162 patients were enrolled between April 1994 and October 1996. Patients attended at trial entry, and at 6 and 12 weeks, where they received 105AD7 or placebo. Study groups were comparable in terms of patient demographics, and time from diagnosis of advanced colorectal cancer (277.1 v 278.6 days). Baseline disease was similar, with 50% of patients having malignancy in at least 2 anatomic sites. Compliance with treatment was poor, with only 50% of patients receiving 3 planned vaccinations. Median survival from randomization date was 124 and 184 days in 105AD7 and placebo arms respectively (P = 0.38), and 456 and 486 days from the date of diagnosis of advanced disease (P = 0.82). 105AD7 vaccination does not prolong survival in patients with advanced colorectal cancer. The reasons for lack of efficacy are unclear, but may reflect the high tumour burden in the patient population, and poor compliance with immunization. Further vaccine studies should concentrate on patients with minimal residual disease. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: anti-idiotypic antibody, colorectal cancer, immunotherapy, 105AD7

Full Text

The Full Text of this article is available as a PDF (89.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amin S., Robins R. A., Maxwell-Armstrong C. A., Scholefield J. H., Durrant L. G. Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res. 2000 Jun 15;60(12):3132–3136. [PubMed] [Google Scholar]
  2. Austin E. B., Robins R. A., Durrant L. G., Price M. R., Baldwin R. W. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology. 1989 Aug;67(4):525–530. [PMC free article] [PubMed] [Google Scholar]
  3. Buckley D. T., Robins A. R., Durrant L. G. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Hum Antibodies Hybridomas. 1995;6(2):68–72. [PubMed] [Google Scholar]
  4. Denton G. W., Durrant L. G., Hardcastle J. D., Austin E. B., Sewell H. F., Robins R. A. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer. 1994 Apr 1;57(1):10–14. doi: 10.1002/ijc.2910570103. [DOI] [PubMed] [Google Scholar]
  5. Durrant L. G., Buckley D. J., Robins R. A., Spendlove I. 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int J Cancer. 2000 Jan 1;85(1):87–92. doi: 10.1002/(sici)1097-0215(20000101)85:1<87::aid-ijc16>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  6. Durrant L. G., Buckley T. J., Denton G. W., Hardcastle J. D., Sewell H. F., Robins R. A. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res. 1994 Sep 15;54(18):4837–4840. [PubMed] [Google Scholar]
  7. Durrant L. G., Maxwell-Armstrong C., Buckley D., Amin S., Robins R. A., Carmichael J., Scholefield J. H. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res. 2000 Feb;6(2):422–430. [PubMed] [Google Scholar]
  8. Jacob L., Somasundaram R., Smith W., Monos D., Basak S., Marincola F., Pereira S., Herlyn D. Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells. Int J Cancer. 1997 May 2;71(3):325–332. doi: 10.1002/(sici)1097-0215(19970502)71:3<325::aid-ijc3>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  9. Maxwell-Armstrong C. A., Durrant L. G., Robins R. A., Galvin A. M., Scholefield J. H., Hardcastle J. D. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7. Gut. 1999 Oct;45(4):593–598. doi: 10.1136/gut.45.4.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Robins R. A., Denton G. W., Hardcastle J. D., Austin E. B., Baldwin R. W., Durrant L. G. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res. 1991 Oct 1;51(19):5425–5429. [PubMed] [Google Scholar]
  11. Spendlove I., Li L., Carmichael J., Durrant L. G. Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res. 1999 May 15;59(10):2282–2286. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES